Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

Net income of $0.8 millionAdjusted EBITDA1 of $1.3 millionPediatric Portfolio net revenue up 86% sequentiallyFirst quarterly sequential prescription increase for both ADHD and Pediatric portfolios sin ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Time in range was similar among pediatric patients with type 1 diabetes who used either the Insulet Omnipod 5 or the Tandem Control IQ.

Luckily, I ran across this video from training expert Steve Del Savio, owner of Pack Leader Dogs. He shared a video on TikTok ...

Chris Johnson operates thermal drones. He said plenty of recoveries are successful, but sometimes they aren’t.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Kenvue shows decent growth but struggles with profitability. Find out why KVUE stock is a 'hold' as cost-cutting efforts face ...